• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25324 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Cooral System for the prevention of oral mucositis
2022     Agency for Care Effectiveness (ACE) Magnetic resonance image guided radiation therapy for patients with cancer
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022     Agency for Care Effectiveness (ACE) Nicotine replacement therapies to aid smoking cessation
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022     Agency for Care Effectiveness (ACE) Sodium zirconium cyclosilicate for treating hyperkalaemia
2022     Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2022     Agency for Care Effectiveness (ACE) Acarbose for treating type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2022     Agency for Care Effectiveness (ACE) Recombinant blood products for prophylaxis and management of haemophilia A and B
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2022     Agency for Care Effectiveness (ACE) GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2023     Agency for Care Effectiveness (ACE) Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2023     Agency for Care Effectiveness (ACE) Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2023     Agency for Care Effectiveness (ACE) Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2024     Agency for Care Effectiveness (ACE) Oxevision for vision-based patient monitoring and management in mental health wards
2023     Agency for Care Effectiveness (ACE) Echinocandins for treating invasive candidiasis
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2025     Agency for Care Effectiveness (ACE) Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025     Agency for Care Effectiveness (ACE) EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025     Agency for Care Effectiveness (ACE) Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
2025     Agency for Care Effectiveness (ACE) Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
2025     Agency for Care Effectiveness (ACE) Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
2025     Agency for Care Effectiveness (ACE) Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
2025     Agency for Care Effectiveness (ACE) Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Onasemnogene abeparvovec for treating spinal muscular atrophy
2025     Agency for Care Effectiveness (ACE) Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
2026     Agency for Care Effectiveness (ACE) Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
2026     Agency for Care Effectiveness (ACE) Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy
2025     Agency for Care Effectiveness (ACE) Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
2025     Agency for Care Effectiveness (ACE) Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
2026     Agency for Care Effectiveness (ACE) Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer
2026     Agency for Care Effectiveness (ACE) Amivantamab for previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small-cell lung cancer
2009     Agency for Health Technology Assessment in Poland (AHTAPol) Clinical effectiveness analysis of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension: a systematic review of randomised controlled trials
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Treatment of pulmonary arterial hypertension in Poland - current practice. Survey results
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Cost-effectiveness analysis of PET-CT positron emission tomography and the diagnostic technologies financed from public sources in oncological diagnostics in Poland
2005     Agency for Healthcare Research and Quality (AHRQ) Effects of omega-3 fatty acids on cancer
2006     Agency for Healthcare Research and Quality (AHRQ) Comparative effectiveness and safety of analgesics for osteoarthritis
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: assessment of screening instruments - a supplemental evidence update for the U.S. Preventive Services Task Force
2005     Agency for Healthcare Research and Quality (AHRQ) Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases
2008     Agency for Healthcare Research and Quality (AHRQ) Screening in primary care settings for illicit drug use: staged systematic review for the United States Preventive Services Task Force
2005     Agency for Healthcare Research and Quality (AHRQ) Effects of omega-3 fatty acids on organ transplantation
2008     Agency for Healthcare Research and Quality (AHRQ) Screening for type 2 diabetes: update of 2003 systematic evidence review for the U.S. Preventive Services Task Force.
2013     Agency for Healthcare Research and Quality (AHRQ) Skin substitutes for treating chronic wounds
2014     Agency for Healthcare Research and Quality (AHRQ) Smoking cessation interventions in pregnancy and postpartum care
2014     Agency for Healthcare Research and Quality (AHRQ) Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force
2011     Agency for Healthcare Research and Quality (AHRQ) Terbutaline pump for the prevention of preterm birth
2014     Agency for Healthcare Research and Quality (AHRQ) Primary care behavioral interventions to prevent or reduce illicit drug and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. preventive services task force
2012     Agency for Healthcare Research and Quality (AHRQ) Systematic review of decision tools and their suitability for patient-centered decisionmaking regarding electronic cardiac devices
2014     Agency for Healthcare Research and Quality (AHRQ) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation
2008     Agency for Healthcare Research and Quality (AHRQ) Impact of gene expression profiling tests on breast cancer outcomes
2014     Agency for Healthcare Research and Quality (AHRQ) Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction
2013     Agency for Healthcare Research and Quality (AHRQ) Use of natriuretic peptide measurement in the management of heart failure
2014     Agency for Healthcare Research and Quality (AHRQ) Meditation programs for psychological stress and well-being
2013     Agency for Healthcare Research and Quality (AHRQ) Chronic venous ulcers: a comparative effectiveness review of treatment modalities
2014     Agency for Healthcare Research and Quality (AHRQ) Benefits and harms of routine preoperative testing: comparative effectiveness
2015     Agency for Healthcare Research and Quality (AHRQ) Emerging approaches to diagnosis and treatment of non–muscle-invasive bladder cancer
2016     Agency for Healthcare Research and Quality (AHRQ) Diabetes medications for adults with type 2 diabetes: an update
2014     Agency for Healthcare Research and Quality (AHRQ) Combination therapy versus intensification of statin monotherapy: an update
2016     Agency for Healthcare Research and Quality (AHRQ) Imaging for the pretreatment staging of small cell lung cancer
2014     Agency for Healthcare Research and Quality (AHRQ) Pharmacologic therapies for the management of crohn's disease: comparative effectiveness